ADAM15 expression is downregulated in melanoma metastasis compared to primary melanoma

Biochemical and Biophysical Research Communications

Volumn 401, Issue 3, 2010, Pages 363-369

  Ungerer, Christopher ^a   Doberstein, Kai ^a   Bürger, Claudia ^a   Hardt, Katja ^a   Boehncke, Wolf Henning ^a   Böhm, Beate ^b   Pfeilschifter, Josef ^a   Dummer, Reinhard ^c   Mihic Probst, Daniela ^d   Gutwein, Paul ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

ADAM15; Invasion; Malignant melanoma; Proliferation

Indexed keywords

ADAM PROTEIN; ADAM15 PROTEIN; GAMMA INTERFERON; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FLUORESCENCE ACTIVATED CELL SORTER; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MELANOMA CELL; METASTASIS; NEVUS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADAM PROTEINS; ANIMALS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; MELANOMA; MEMBRANE PROTEINS; MICE; NEOPLASM METASTASIS; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 77958150128     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.09.055     Document Type: Article

References (21)

1. Liu D., O'Day S.J., Yang D., Boasberg P., Milford R., Kristedja T., Groshen S., Weber J. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin. Cancer Res. 2005, 11:1237-1246.
2. Lee S.B., Schramme A., Doberstein K., Dummer R., Abdel-Bakky M.S., Keller S., Altevogt P., Oh S.T., Reichrath J., Oxmann D., Pfeilschifter J., Mihic-Probst D., Gutwein P. ADAM10 is upregulated in melanoma metastasis compared with primary melanoma. J. Invest. Dermatol. 2010, 130:763-773.
3. Kratzschmar J., Lum L., Blobel C.P. Metargidin, a membrane-anchored metalloprotease-disintegrin protein with an RGD integrin binding sequence. J. Biol. Chem. 1996, 271:4593-4596.
4. Reiss K., Saftig P. The "a disintegrin and metalloprotease" (ADAM) family of sheddases: physiological and cellular functions. Semin. Cell Dev. Biol. 2009, 20:126-137.
5. Najy A.J., Day K.C., Day M.L. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J. Biol. Chem. 2008, 283:18393-18401.
6. Kuefer R., Day K.C., Kleer C.G., Sabel M.S., Hofer M.D., Varambally S., Zorn C.S., Chinnaiyan A.M., Rubin M.A., Day M.L. ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. Neoplasia 2006, 8:319-329.
7. Trochon-Joseph V., Martel-Renoir D., Mir L.M., Thomaidis A., Opolon P., Connault E., Li H., Grenet C., Fauvel-Lafeve F., Soria J., Legrand C., Soria C., Perricaudet M., Lu H. Evidence of antiangiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin. Cancer Res. 2004, 64:2062-2069.
8. Mihic-Probst D., Kuster A., Kilgus S., Bode-Lesniewska B., Ingold-Heppner B., Leung C., Storz M., Seifert B., Marino S., Schraml P., Dummer R., Moch H. Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int. J. Cancer 2007, 121:1764-1770.
9. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
10. Lee S.B., Schramme A., Doberstein K., Dummer R., Abdel-Bakky M.S., Keller S., Altevogt P., Oh S.T., Reichrath J., Oxmann D., Pfeilschifter J., Mihic-Probst D., Gutwein P. ADAM10 is upregulated in melanoma metastasis compared with primary melanoma. J. Invest. Dermatol. 2009, 130:763-773.
11. Kleino I., Ortiz R.M., Huovila A.P. ADAM15 gene structure and differential alternative exon use in human tissues. BMC Mol. Biol. 2007, 8:90.
12. Duffy M.J., McKiernan E., O'Donovan N., McGowan P.M. Role of ADAMs in cancer formation and progression. Clin. Cancer Res. 2009, 15:1140-1144.
13. Chen Q., Meng L.H., Zhu C.H., Lin L.P., Lu H., Ding J. ADAM15 suppresses cell motility by driving integrin alpha5beta1 cell surface expression via Erk inactivation. Int. J. Biochem. Cell Biol. 2008, 40:2164-2173.
14. Lum L., Reid M.S., Blobel C.P. Intracellular maturation of the mouse metalloprotease disintegrin MDC15. J. Biol. Chem. 1998, 273:26236-26247.
15. Zhang X.P., Kamata T., Yokoyama K., Puzon-McLaughlin W., Takada Y. Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3. J. Biol. Chem. 1998, 273:7345-7350.
16. Zhong J.L., Poghosyan Z., Pennington C.J., Scott X., Handsley M.M., Warn A., Gavrilovic J., Honert K., Kruger A., Span P.N., Sweep F.C., Edwards D.R. Distinct functions of natural ADAM-15 cytoplasmic domain variants in human mammary carcinoma. Mol. Cancer Res. 2008, 6:383-394.
17. Reguly T., Wrana J.L. In or out? The dynamics of Smad nucleocytoplasmic shuttling. Trends Cell Biol. 2003, 13:216-220.
18. Albino A.P., Davis B.M., Nanus D.M. Induction of growth factor RNA expression in human malignant melanoma: markers of transformation. Cancer Res. 1991, 51:4815-4820.
19. Rodeck U., Melber K., Kath R., Menssen H.D., Varello M., Atkinson B., Herlyn M. Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. J. Invest. Dermatol. 1991, 97:20-26.
20. Rodeck U., Bossler A., Graeven U., Fox F.E., Nowell P.C., Knabbe C., Kari C. Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. Cancer Res. 1994, 54:575-581.
21. Krasagakis K., Tholke D., Farthmann B., Eberle J., Mansmann U., Orfanos C.E. Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br. J. Cancer 1998, 77:1492-1494.